IMMX news

Immix Biopharma reported a 89% complete response rate across late-stage AL Amyloidosis patients. This strong interim data strengthens the company's claim of developing a potential best-in-class therapy.

Immix Biopharma is conducting an underwritten public offering of approximately 16.8 million shares of common stock at $0.01 per share with Morgan Stanley as lead underwriter. The offering provides capital for the biopharmaceutical company under its existing shelf registration statement.

Immix announced interim results from its NEXICART-2 Phase 2 trial showing a 95% complete response rate (19 of 20 patients) in relapsed/refractory AL Amyloidosis patients treated with NXC-201, with all CRs achieved within one year and no relapses observed. The company plans to initiate a Phase 3 tria…